Search the Newsreel

Viking Holdings stock hits all-time high of 105.84 USD

Viking Holdings Ltd (VIK) stock reached an all-time high of $105.84, demonstrating a strong performance over the past year with approximately 78% total return. Despite being potentially overvalued according to InvestingPro analysis, the company boasts a low P/E ratio relative to near-term earnings growth, …

Viking Holdings Ltd. $VIK Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Viking Holdings Ltd. (VIK) by 19.8% in Q1 2026, now owning 581,948 shares valued at $42.8 million. Institutional investors hold 98.84% of VIK, and analysts maintain a "Moderate Buy" rating with an average price target …

First Trust Advisors LP Buys 41,517 Shares of Viking Holdings Ltd. $VIK

First Trust Advisors LP increased its stake in Viking Holdings Ltd. by 34.8% in Q1 2026, acquiring 41,517 additional shares for a total of 160,947 shares valued at $11.8 million. Institutional investors now own 98.84% of the company, which recently reported 17.5% year-over-year revenue …

12,849 Shares in Viking Holdings Ltd. $VIK Purchased by Bull Harbor Capital LLC

Bull Harbor Capital LLC recently acquired 12,849 shares of Viking Holdings Ltd. (NYSE: VIK) valued at approximately $944,000 during the first quarter. This purchase contributes to the 98.84% institutional ownership of the company. Despite some insider selling, analysts maintain a "Moderate Buy" rating for …

Viking Acquisition Corp. I Revenue Breakdown – NYSE:VACI/W

This Insider Has Just Sold Shares In Viking Therapeutics

Viking Therapeutics President Brian Lian recently sold US$4.9 million worth of stock, representing 6.3% of his holding. While insiders sold more than they bought over the last year, the company still reports 2.4% insider ownership, which suggests reasonable alignment with shareholders. The article notes …

Viking Therapeutics (Nasdaq: VKTX) deepens loss as obesity and NASH drugs advance

Viking Therapeutics reported a net loss of $286.3 million for the first half of 2026, widening from $111.2 million a year prior, due to increased R&D spending on its obesity and NASH drug pipeline. Despite the losses, the company maintains strong liquidity with $501.7 …

Earnings call transcript: Viking Therapeutics posts Q2 2026 loss beat

Viking Therapeutics (VKTX) reported a narrower-than-expected loss of $1.10 per share for Q2 2026, surpassing analyst estimates of $1.23, although its net loss widened compared to the previous year due to increased R&D spending. The company is advancing its lead obesity drug candidate, VK2735, …

Viking Holdings Ltd. $VIK Shares Acquired by Lazard Asset Management LLC

Lazard Asset Management LLC significantly increased its stake in Viking Holdings Ltd. (NYSE:VIK) by 555.1% in the first quarter, now holding 136,774 shares valued at $10.05 million. This move is part of broader institutional interest, with hedge funds and institutional investors owning 98.84% of …

Viking Therapeutics Stock Moves Lower: What's Going On?

Viking Therapeutics (NASDAQ: VKTX) stock decreased by 4.49% despite reporting a narrower-than-expected net loss of $1.10 per share for the quarter ending June 30. This loss was primarily due to increased R&D costs which nearly doubled. The company maintains a strong cash position and …

VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs

Viking Therapeutics (VKTX) reported a narrower-than-expected Q2 2026 loss of $1.10 per share, surpassing the Zacks Consensus Estimate of a $1.21 loss, despite a significant 92.4% surge in R&D expenses due to pipeline development, primarily for its lead obesity candidate VK2735. The company is …

Viking Therapeutics Advances VK2735 Oral Program Into Phase 3 Trials

Viking Therapeutics is moving its oral tablet formulation of VK2735 into Phase 3 trials in Q4 2026, building on its strong cash position of $502 million and two fully enrolled Phase 3 subcutaneous trials. The company aims for VK2735 to be the first oral …

Viking Therapeutics Inc (VKTX) (Q2 2026) Earnings Call Highlights: Advancing Obesity Pipeline ...

Viking Therapeutics reported a significant net loss increase in Q2 2026 due to higher R&D expenses, yet remains optimistic about its obesity pipeline. The company highlighted progress in its VK2735 Phase III program, with upcoming oral trials, and the entry of VK3019 into Phase …

VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t

Viking Therapeutics (VKTX) stock has underperformed its GLP-1 peers in July, but CEO Brian Lian believes its obesity drug VK2735 could offer a competitive edge through multiple treatment options, including weekly injection, daily pill, and potentially less-frequent dosing for maintenance. The company's lead drug …

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- …

Viking Holdings Ltd. $VIK Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. significantly increased its stake in Viking Holdings Ltd. by 27.6% in the first quarter, now owning 54,508 shares valued at approximately $4.0 million. This move is part of a broader trend where institutional investors and hedge funds hold nearly 99% …

3 Biotech Stocks With Massive Upside to Buy Before August Starts

Quick Read REGN sits 15% below its year-start price despite strong earnings, while MRNA has surged 177% into an August 5 FDA flu vaccine ruling. VKTX carries 175% analyst upside potential but remains pre-revenue, making its dual GLP-1/GIP Phase 3 obesity trials a binary …

Stocks to Watch Today: Graphite India, Rail Vikas Nigam, Larsen and Toubro, Birlasoft, Tata Capital,...

Viking Holdings Ltd. $VIK Shares Purchased by Evercore Wealth Management LLC

Evercore Wealth Management LLC increased its stake in Viking Holdings Ltd. (NYSE:VIK) by 0.9% in the first quarter, bringing its total holdings to 1.67 million shares valued at $122.9 million. Institutional ownership of Viking remains very high at 98.84%, with several other funds also …

Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case

Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, have declined by 46% over the past two years. There are several reasons for this. First, longtime shareholders decided to pocket some profits after Viking Therapeutics reported excellent mid-stage results for its leading candidate, subcutaneous …

VIK|Viking Holdings Ltd|Price:104.560|Chg%:+1.420

This article provides a detailed financial and analytical overview of Viking Holdings Ltd (VIK), including its current stock price, market trends, key financials, and analyst ratings. It highlights the company's strong fundamentals and growth potential in the Hotels & Entertainment Services industry, despite some …

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these …

Viking Holdings (VIK) Oberammergau Voyages Put Its Valuation Back In Focus

Viking Holdings (VIK) has gained attention with new 2030 Oberammergau Passion Play river voyages and a Summer Sale, following a strong stock performance. While analysts consider it fairly priced around $102.09, Simply Wall St's DCF model suggests a higher fair value of $177.53 per …

Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness

Insiders at Viking Therapeutics recently sold shares worth US$15 million, with the average selling price ranging from US$66.00 to US$89.00. This significant insider selling event could suggest that the stock might be overvalued, prompting investors to consider various valuation metrics. Despite the selling, the …

Sculptor Capital LP Cuts Stock Holdings in Viking Holdings Ltd. $VIK

Sculptor Capital LP reduced its stake in Viking Holdings Ltd. (NYSE:VIK) by 4.3% in the first quarter, selling 65,000 shares but still retaining 1.435 million shares valued at approximately $105.4 million. Despite this reduction, institutional investors collectively own 98.84% of VIK, and analysts maintain …

Viking Holdings Ltd. $VIK Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its stake in Viking Holdings Ltd. by 1.7% in the first quarter, selling 13,400 shares but still owning 759,204 shares valued at $55.8 million. Despite this, other institutions increased their holdings, and the company's shares are trading near their 52-week …

VACI|Viking Acquisition I Ord Shs Class A|Price:10.129|Chg%:-0.001

This article provides detailed financial data and market trends for Viking Acquisition I Ord Shs Class A (VACI). It includes real-time quotes, key financial figures, technical indicators, and a company overview for the blank check company. The article also lists major shareholders and related …

Viking Holdings Ltd (VIK) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Viking Holdings Ltd (VIK), listing major shareholders and providing a breakdown of institutional holdings. Key shareholders include Viking Capital Corp. (34.06%), Capital Research Global Investors (7.65%), and CPP Investments (6.33%). The report also shows changes in institutional …

Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29

Viking Therapeutics (NASDAQ:VKTX) stock is under scrutiny for its cash burn ahead of its Q2 earnings report on July 29. Analysts expect increased losses due to surging research and operating expenses, prompting investor focus on cash levels, expenditure, and clinical trial timelines. The company …

Viking Holdings Ltd (VIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Viking Holdings Ltd (VIK), detailing its performance by business segments and regional contributions. As of April 6, the company's total revenue was 6.49 billion USD, with River cruises generating 3.07 billion USD (47.23%) and Ocean cruises 2.87 …

Viking Therapeutics, Inc. Revenue Breakdown – DUS:1VT

This article provides financial information for Viking Therapeutics, Inc. (DUS:1VT) on the Düsseldorf Stock Exchange. It focuses on the company's revenue breakdown, including top segments and regional performance, sourced from FactSet and ICE Data Services.

Cumberland Partners Ltd Has $2.57 Million Stake in Viking Holdings Ltd. $VIK

Cumberland Partners Ltd significantly reduced its stake in Viking Holdings Ltd. (NYSE:VIK) by 50% in the first quarter, now holding 35,000 shares valued at $2.57 million. Insider sales have also occurred, with EVP Richard Marnell selling a substantial number of shares, while institutional ownership …

Vikram Solar Limited Revenue Breakdown – NSE:VIKRAMSOLR

Viking Holdings Ltd (VIK) Financial Health: Profitability & Balance Sheet Analysis

Viking Holdings Ltd (VIK) currently holds a robust financial score of 6.96, ranking 77th in the Hotels & Entertainment Services industry. The company demonstrated high operating efficiency with its latest quarterly revenue reaching $1.05 billion, a 17.47% year-over-year increase, and net profit growing by …

VKTX|Viking Therapeutics Inc|Price:34.770|Chg%:-0.620

Viking Therapeutics Inc (VKTX) is a clinical-stage biopharmaceutical company focused on treatments for metabolic and endocrine disorders, with lead programs including VK2735 and VK2809. The company's stock is currently trading at $34.77, down 1.75%, and analysts have a "Buy" rating with an average target …

Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News

Viking Therapeutics (VKTX) stock has seen significant returns over the past five years, but current valuations suggest it may be overvalued, particularly when considering its price-to-book (P/B) ratio. The high valuation is partly driven by excitement around new diabetes and metabolic therapies, though the …